BioSource International announced in February 2005 that it had commercialised the first multiplex protein microarray able to reproducibly measure multiple phosphorylated proteins in one sample
Through collaboration with Whatman Schleicher and Schuell, BioSource produced a novel assay capable of altering the methods whereby scientists can study protein phosphorylation for the research of disease.
Whatman Schleicher and Schuell is a leader in protein array technology beginning with the development of the Fast Slide, the premier protein arraying surface.
The nitrocellulose surface, combined with BioSource's extensive experience in signal transduction assay development, has led to a highly sensitive, rapid and reproducible assay that simultaneously quantifies ten phosphoproteins.
BioSource will offer a scanning service allowing any researcher to use the array without the barrier of instrumentation.
"Mercator PhosphoArrays provide a wealth of information about a signaling system from one of the most innovative technologies on the market," said Terrance Bieker, BioSource's president and chief executive officer.
"The information resulting from the application of this technology should provide scientists with important data on cell systems across multiple pathways, giving insight into disease states".
Robert Negm, director, business development of Whatman Schleicher and Schuell stated: "We are very pleased with this product resulting from our partnership with BioSource, as it will substantially increase the number of cell-signalling scientists who may benefit from combining our focus in protein microarray technology with BioSource's strengths in developing market-leading immunoassay reagents".
This multiplex protein microarray product is the first of what is intended to be a broad line of BioSource protein microarrays capable of targeting disease research in oncology, neurobiology and inflammation.
The product enhances BioSource's position as a market leader in providing quantitative signal transduction phosphoElisas.
